Curespec

Noninvasive Electro-hydraulic Acoustic Therapy

Health Tech & Life Sciences
Active
Series A Yehud-Monosson, Israel Founded 2020
Last updated 2026-06-18
Total raised
$7.4M
Last: 2023-01
Stage
Series A
Founded
2020
Headcount
9
HQ
Yehud-Monosson, Israel
Sector
Health Tech & Life Sciences

About

Curespec offers a medical device solution that uses noninvasive shockwave therapy for the treatment of hypertension and chronic kidney disease (CKD). The company’s technology is designed to generate new blood vessels and restore function to damaged tissue.

Curespec’s first market-ready product, Nephrospec, is a safe, low-intensity, noninvasive shockwave device delivering electro-hydraulic acoustic therapy (eHAT) intended for the interrelated treatment of hypertension and CKD. Designed to save up to 80% of costs while reducing suffering and needless loss of life, Nephrospec can improve kidney function in weeks, delay onset of dialysis with outpatient treatment, and function as a complementary solution to optimal medical care for hypertension and CKD.

Curespec has obtained CE and AMAR approval in Europe and Israel respectively.

Funding history · 2 rounds · $7.4M total

2023-01
$1.0M
2020-06
$6.4M

Q&A

What is Curespec's primary focus in the medical device sector?
Curespec specializes in a medical device solution that employs noninvasive shockwave therapy for treating hypertension and chronic kidney disease (CKD). Its technology aims to generate new blood vessels and restore function to damaged tissue.
What is Curespec's flagship product?
Curespec's first market-ready product is Nephrospec, a noninvasive shockwave device that delivers electro-hydraulic acoustic therapy (eHAT) for the interrelated treatment of hypertension and CKD.
What regulatory approvals has Curespec obtained for its products?
Curespec has obtained CE approval in Europe and AMAR approval in Israel for its medical device solutions.
When was Curespec founded?
Curespec was founded in December 2020.
What is the total amount of funding Curespec has raised to date?
Curespec has raised a total of $7,400,000 in funding.
When was Curespec's most recent funding round?
Curespec's most recent funding round occurred in January 2023, raising $1,000,000.
What is Curespec's current employee count?
Curespec has 9 employees, falling within the 1-10 employee bucket.
Where is Curespec's headquarters located?
Curespec's headquarters is located in Yehud-Monosson, Center District, Israel.

Team · 1

Founder · Co-founder & Active Chairman
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
Healthcare & Life SciencesHealthcareProvidersPatients
Business model
B2CB2B

Highlights

1 PatentsVerified

Tags

chronic-diseasetissue-regenerationcardiologypain-reliefhospitalsnephrologyblood-pressurenon-invasivedialysisclinicstreatmentsmedical-devicesmedical-technologies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)